Abstract
Stem cell replacement has emerged as the novel therapeutic strategy for Parkinsons disease (PD). Control of motor behavior is lost in PD due to the selective degeneration of mesencephalic dopamine neurons (DA) in the substantia nigra. This progressive loss of DA neurons results in devastating symptoms for which there is no cure. Debilitating side effects often result from chronic pharmacological treatment, hence current investigations into cell transplantation therapy as a substitute and/or adjuvant to other therapeutics. Clinical trials with fetal DA tissue have provided evidence that cell transplantation could be a viable alternative. Limited availability of fetal tissue, combined with variable outcome led to emphasis on other sources of cells, such as stem cells. This review focuses on three stem cell sources (embryonic, neural, and adult mesenchymal). Also discussed is the molecular differentiation into mature DA neurons, the various protocols that have been developed to generate DA neurons from various stem cells, and the current state of stem cell therapy for PD.
Keywords: Parkinson's disease, dopamine, stem cells, development, transplantation, neural repair, cell replacement
Current Neurovascular Research
Title: Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Volume: 4 Issue: 2
Author(s): Katarzyna A. Trzaska and Pranela Rameshwar
Affiliation:
Keywords: Parkinson's disease, dopamine, stem cells, development, transplantation, neural repair, cell replacement
Abstract: Stem cell replacement has emerged as the novel therapeutic strategy for Parkinsons disease (PD). Control of motor behavior is lost in PD due to the selective degeneration of mesencephalic dopamine neurons (DA) in the substantia nigra. This progressive loss of DA neurons results in devastating symptoms for which there is no cure. Debilitating side effects often result from chronic pharmacological treatment, hence current investigations into cell transplantation therapy as a substitute and/or adjuvant to other therapeutics. Clinical trials with fetal DA tissue have provided evidence that cell transplantation could be a viable alternative. Limited availability of fetal tissue, combined with variable outcome led to emphasis on other sources of cells, such as stem cells. This review focuses on three stem cell sources (embryonic, neural, and adult mesenchymal). Also discussed is the molecular differentiation into mature DA neurons, the various protocols that have been developed to generate DA neurons from various stem cells, and the current state of stem cell therapy for PD.
Export Options
About this article
Cite this article as:
Trzaska A. Katarzyna and Rameshwar Pranela, Current Advances in the Treatment of Parkinsons Disease with Stem Cells, Current Neurovascular Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720207780637199
DOI https://dx.doi.org/10.2174/156720207780637199 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor
Current Pharmaceutical Design Inflammation, High Density Lipoprotein and Endothelium
Current Medicinal Chemistry Goal Directed Fluid Therapy
Current Pharmaceutical Design Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort
Current Alzheimer Research Novel Approach to Treat Insulin Resistance, Type 2 Diabetes, and the Metabolic Syndrome: Simultaneous Activation of PPARα, PPARγ, and PPARδ
Current Diabetes Reviews Binding Interactions of Forskolin with Human Serum Albumin: Insights from In silico and Spectroscopic Studies
Current Chemical Biology Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Long-term Success and Follow-up After Atrial Fibrillation Ablation
Current Cardiology Reviews The Role of Electrospinning in the Emerging Field of Nanomedicine
Current Pharmaceutical Design The Epidemiology of Adiposity and Dementia
Current Alzheimer Research Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury
Current Drug Targets Emerging Roles for Vasoactive Peptides in Diagnostic and Therapeutic Strategies Against Atherosclerotic Cardiovascular Diseases
Current Protein & Peptide Science Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Current Topics in Medicinal Chemistry Could Resveratrol be a Useful Drug for the Treatment of Malignant Hemopathies?
Recent Patents on Anti-Cancer Drug Discovery Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Exploitation of Some Natural Products for the Prevention and/or Nutritional Treatment of SARS-CoV2 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Is the Use of Cholesterol-Lowering Drugs for the Prevention of Cardiovascular Complications in Type 2 Diabetics Evidence-Based? A Systematic Review
Reviews on Recent Clinical Trials